期刊文献+

贝伐单抗联合曲安奈德治疗穿透性角膜移植术后新生血管 被引量:3

Prevent effect of Bevacizumab and Triamcinolone acetonide on corneal neovascularization induced by penetrating keratoplasty
下载PDF
导出
摘要 目的:观察球结膜下注射贝伐单抗和曲安奈德治疗穿透性角膜移植术后新生血管的临床疗效。方法:对19例20眼因眼外伤行穿透性角膜移植术后3mo,新生血管增生达到Ⅲ度以上患眼随机分为四组。A组:对照组;B组:贝伐单抗2.5mg(0.1mL);C组:贝伐单抗及曲安奈德各0.1mL;D组:曲安奈德0.1mL;每月1次,共两次球结膜下注射药物。结果:平均随访3a,B组和C组视力保持稳定或稍有增进,新生血管和免疫反应明显减退(P<0.01),患者眼痛、畏光流泪症状减轻。结论:贝伐单抗联合曲安奈德在治疗穿透性角膜移植术后新生血管的过程中能够有效减退新生血管,并减轻排斥反应,对保持植片的透明性有积极的治疗作用。 AIM: To observe the clinical effect subconjunctival bevacizumab and triamcinolone acetonide ( TA ) on corneal neovascularization ( CNV) induced by penetrating keratoplasty. METHODS: Nineteen patients (20 eyes) with CNV induced by penetrating keratoplasty after 3mo were selected and were divided into 4 groups randomly: Group A was control group, group B was treated by subconjunctival of bevacizumab (2.5mg, 0. l mL), group C was treated by subconjunctival of bevacizumab (2.5mg, 0,1mL) and TA (4mg, 0.1mL-1, group D was treated by subconjunctival of TA (4mg, 0. lmL), one time each month, twice. RESULTS: The average follow-up period was 3a. Visual acuity of groups B and C kept stable or increase slightly. CNV and immunologic rejection were lighten (, P〈0.01 ), symptomatic of ophthalmalgia and photophobia relief synchronous. CONCLUSION : Treatment of subconjunctival bevacizumab and TA can effectively inhibite CNV andimmunologic rejection, also has the therapeutical effect to maintain implant transparence after penetrating keratoplasty.
出处 《国际眼科杂志》 CAS 2014年第11期2016-2018,共3页 International Eye Science
基金 云南省教育厅基金项目(No.2010c101)~~
关键词 贝伐单抗 曲安奈德 穿透性角膜移植 角膜新生血管 bevacizumab triamcinolone acetonide penetrating keratoplasty corneal neovascularization
  • 相关文献

参考文献10

  • 1李世宏,叶剑,贺翔鸽,李翔骥.Avastin结膜下注射及眼液治疗角膜新生血管1例[J].国际眼科杂志,2009,9(5):1010-1010. 被引量:10
  • 2Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. Faseb J 2002 ; 16 (2) :267-269.
  • 3张研,陆晓和.角膜新生血管治疗进展[J].中国实用眼科杂志,2008,26(5):427-431. 被引量:5
  • 4高峨嵋,徐建明.VEGF靶向药Avastin治疗实体瘤的研究进展[J].中国肿瘤临床与康复,2006,13(5):473-475. 被引量:11
  • 5Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000 ;41 (9) :2514-2522.
  • 6Zaki AA, Fafid SF. Subconjunctival bevacizumab for corneal neovascularizafion. Acta Ophthalmol 2010;88(8) :868-871.
  • 7Vassileva PI, Hergeldzhieva TG. Bevacizumab use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmo12009 ; 247 ( 12 ) : 1701-1706.
  • 8Kemt M, Welge- Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior and posterior segment cultured cells. Ophthalmologe 2007 ; 104( 11 ) :965-971.
  • 9肖骏,魏世辉.糖皮质激素在眼科的应用[J].中国实用眼科杂志,2004,22(12):960-963. 被引量:22
  • 10Murata M, Shimizu S, Horiuehi S, et al . Inhibitory effect of triameinolone aeetonide on corneal neovaseularization. Graefes Arch Clin Exp Ophthalmol 2006 ;244 ( 2 ) : 205-209.

二级参考文献58

共引文献43

同被引文献121

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部